InvestorsHub Logo
Followers 7
Posts 1173
Boards Moderated 0
Alias Born 11/13/2018

Re: AVII77 post# 207833

Sunday, 08/11/2019 8:55:43 AM

Sunday, August 11, 2019 8:55:43 AM

Post# of 425622
Thank you for your reply. I have not been around as long as you and appreciate your perspective. The Adcom questions in this previous example were about cardiovascular risk reduction. Despite the similarities, Why do you think this is just about MO? This seems counter-intuitive to me.

"This ADCOM wasn't convened to argue 135 vs 150 trigs on the label or primary vs secondary population. This ADCom was convened to explore and discuss the MO placebo"
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News